Business Wire

TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery

13.9.2022 15:02:00 EEST | Business Wire | Press release

Share

Abiomed (Nasdaq: ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference, held in Boston from September 16 to 19.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005521/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Impella 5.5 with SmartAssist delivers full cardiac support with maximum unloading, allowing the heart to rest and recover. (Graphic: Business Wire)

During the conference, physician-researchers will present clinical data demonstrating Impella leads to higher survival rates for cardiogenic shock patients and quality of life improvements for heart failure patients. Additional presentations and live cases will describe how Impella innovation and best practices have advanced safety and ease-of-use. Attendees can also receive hands-on Impella training and learn about future Impella technology.

Clinical Data Presentations:

Impella will be featured in presentations on topics that include a new analysis of data from the STEMI-DTU pilot randomized controlled trial and new data on cardiogenic shock and myocarditis outcomes from the J-PVAD registry in Japan. The J-PVAD registry is overseen by 10 Japanese professional societies, including the Japanese Circulation Society.

Abiomed’s preCARDIA technology to treat acute decompensated heart failure (ADHF) will be featured in two presentations that provide data showing preCARDIA reduces stressed blood volume and improves urine sodium excretion in ADHF patients.

Additionally, Abiomed will host two symposia with physician-researchers discussing the benefits of Impella as a therapy for patients in cardiogenic shock and Impella-supported high-risk PCI. They are:

  • From Shock Spiral to Survival: Achieving Heart Recovery in Cardiogenic Shock – This in-person symposium takes place on Saturday, September 17, from 12:45–1:45 pm EDT in the TCT Presentation Theatre. Navin K. Kapur, MD, Tufts Medical Center, Boston; Katherine Kunkel, MD, Piedmont Heart Institute, Atlanta; Junya Ako, MD, Kitasato University Hospital, Tokyo; and Jay Giri, MD, MPH, Penn Medicine, Philadelphia, will present on best practices for Impella use to improve cardiogenic shock survival. A panel discussion will take place that will also include William O’Neill, MD and Mir Babar Basir, DO, from Henry Ford Hospital, Detroit.
  • The CAD’s Out of the Bag: Achieving Heart Recovery in High-Risk Revascularization – This symposium is in-person and will be live streamed from the TCT World Connect Theatre on Sunday, September 18, from 12:30–1:30 pm EDT. Jonathan Hill, MD, Royal Brompton and Harefield Hospital, London; and Kate Kearney, MD, University of Washington, Seattle, will discuss clinical trials and best practices for Impella-supported high-risk PCI. Additionally, Navin K. Kapur, MD, Tufts Medical Center, Boston, will discuss ventricular unloading and what can be learned from the STEMI-DTU randomized controlled trial. A panel discussion will take place that will also include Gregg Stone, MD, Mount Sinai Health System, New York; Amir Kaki, MD, Ascension St. John Hospital, Detroit; and Cindy Grines, MD, Northside Hospital, Atlanta.

A detailed agenda for each symposium is available at this link on the TCT website.

Technology and Training:

Physicians attending the conference can receive hands-on Impella best practice training in the TCT Training Pavilion on topics such as access and closure, Impella RP with SmartAssist insertion and advanced Impella management. The esteemed faculty teaching these courses are Rajiv Tayal, MD, Valley Health System, Ridgewood, NJ; Robert Salazar, MD, Memorial Hermann, Houston; and Dan Burkhoff, MD, PhD, Cardiovascular Research Foundation. A detailed agenda for each training is available at this link on the TCT website.

Conference attendees are invited to visit the Abiomed booth, in the TCT Exhibit Hall. Abiomed’s booth will feature the latest Impella technology, including Impella 5.5 with SmartAssist and Impella RP with SmartAssist. Future pipeline technology will be available to preview, including Impella ECP, Impella RP Flex, Impella BTR and preCARDIA. Additionally, advanced Impella trainers will be available to answer questions about Impella’s new heparin-free purge, provide a hands-on experience with the Impella simulator and guide attendees through Abiomed’s new virtual reality training technology.

Live Daily Recap Program:

Abiomed’s TCT daily recap program will broadcast live from 6:00–6:30 pm EDT on Saturday, September 17 through Monday, September 19. The program will summarize the day’s news from TCT. It will be hosted by Abiomed’s chief medical officer, Chuck Simonton, MD, and Abiomed’s vice president for professional education and medical communication, Seth Bilazarian, MD. To watch live, log on to www.heartrecovery.com.

ABOUT IMPELLA HEART PUMPS

The Impella 2.5® and Impella CP® with SmartAssist® are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.

Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD® and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

Impella RP® and Impella RP® with SmartAssist are U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com.

FORWARD-LOOKING STATEMENTS

Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com

Investor Contact:
Todd Trapp
Executive Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Workiva Advances Regulatory Work with AI Innovation15.9.2026 18:00:00 EEST | Press release

Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, unveiled dozens of new product and platform innovations at Amplify 2026, the company’s annual conference attended by thousands of finance, accounting, sustainability, risk, and compliance leaders. Workiva Debuts Agent Studio Workiva introduced Agent Studio, a landmark platform capability that empowers users to quickly build, customize, and deploy AI agents in Workiva's trusted platform. By combining AI reasoning with Workiva's native platform capabilities, enterprise knowledge, and governed workflows, Agent Studio enables users to automate sophisticated manual business processes without writing any code. Organizations can enrich agents with company-specific knowledge and context, tailor them to their own processes, and schedule automations to execute recurring work. “With Agent Studio, we're putting the power to build in the hands of the people who know the work and their company the b

Study: Heatwaves Increase Cough Urge, Which Salt Aerosols Reduce15.9.2026 16:15:00 EEST | Press release

SC Therapeutics, with University North Carolina, Imperial College London, and Boston University, announced publication on Tuesday in Nature Scientific Reports of results from a multi-institutional study indicating that the aridity inherent in heatwaves increases cough hypersensitivity in human airways by collapsing mucus onto cilia in a manner common to chronic respiratory diseases, such as cystic fibrosis, and asthma. The researchers find that alkaline aerosols of magnesium salts reverse mucosal collapse for several hours, and reduce cough hypersensitivity as reflected in placebo-adjusted suppression of daily cough bout rate (59%, p=0.03) and persistence of suppression post treatment for 1 to 3 weeks in a randomized, double-blind, placebo-controlled study of 10 refractory chronic cough patients. “Paris recorded 5,764 excess deaths between 17 June and 2 July, a period of time during which we report atmospheric aridity in the city increased approximately 3-fold relative to the 35 year a

ADM’s Fourth Annual Regenerative Agriculture Report Highlights Growing Resilience Across the Food System15.9.2026 16:00:00 EEST | Press release

ADM (NYSE: ADM), a global leader in innovative solutions from nature, today released its fourth annual regenerative agriculture report, showing how its programs are supporting farmers, strengthening agricultural supply chains and delivering measurable environmental outcomes around the world. “Resilience starts on the farm. By improving and protecting soil health, farmers can be better equipped to adapt to changing conditions and maintain productive operations,” said Greg Morris, SVP and President, Ag Services and Oilseeds, ADM. “That resilience can extend across the value chain, helping strengthen the food system we all depend on.” In 2025, ADM’s regenerative agriculture programs engaged more than 56,000 farmers across approximately 4.6 million acres, 11 countries and 10 crops. Compared with regional benchmarks, the programs resulted in approximately 946,000 metric tons of CO₂e reductions. “ADM views agriculture as a powerful way to meet evolving customer needs, and our work in regener

Diligent Unveils New Agentic Capabilities in Diligent One to Power the Future of Governance, Risk and Compliance15.9.2026 16:00:00 EEST | Press release

Diligent, the AI leader in governance, risk and compliance (GRC) solutions, today announced a major enhancement to Diligent One, its native AI platform, at Gartner’s Enterprise Risk, Audit and Compliance Conference (ERAC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915941016/en/ “For many organizations, GRC work is slowed by fragmented systems, manual coordination and time-consuming reporting processes,” said Brian Stafford, President and CEO of Diligent. “Our latest agentic capabilities help teams cut through that complexity by connecting context, surfacing what matters and driving faster execution — while keeping governance and professional judgement at the center." An orchestration agent that coordinates work and approvals The orchestration agent in Diligent One gives GRC professionals a natural-language interface to coordinate audit and risk work. Instead of simply answering questions, it enables users to describe

Unifocus Launches AI-Powered Platform to Transform Workforce and Operations Management in Hospitality15.9.2026 16:00:00 EEST | Press release

The global hospitality technology provider, Unifocus, has announced the launch of its newest AI platform, Unifocus Claira. Unifocus Claira is an industry first end-to-end workforce management and operations platform, purpose-built to give hoteliers and above-property hospitality organizations complete visibility across the workforce lifecycle through one cohesive system. By replacing the patchwork of disconnected tools, multiple technology stacks and siloed data systems that have traditionally been used to manage labor and operations processes, Unifocus Claira delivers one connected AI-native platform, providing customers with a comprehensive and organized view of their workforce and operations data. This unified data foundation powers advanced AI capabilities designed to accelerate decision-making, improve operational performance and drive business growth. Importantly, Unifocus Claira is also the first end-to-end platform of its calibre, purpose-built specifically for the select servi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye